Last update 19 Dec 2024

Escitalopram Oxalate

Overview

Basic Info

SummaryEscitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders.
Drug Type
Small molecule drug
Synonyms
Cipralex, Entact, Escitalopram
+ [17]
Mechanism
5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), SERT inhibitors(Serotonin transporter inhibitors)
Originator Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure

Molecular FormulaC22H23FN2O5
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N
CAS Registry219861-08-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Depressive Disorder
CN
31 Aug 2005
Panic Disorder
CN
31 Aug 2005
Generalized anxiety disorder
US
18 Dec 2003
Anxiety Disorders
SE
07 May 2002
Depressive Disorder, Major
SE
07 May 2002
Obsessive-Compulsive Disorder
SE
07 May 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
US
01 May 2009
SchizophreniaPhase 3
IL
01 Nov 2004
Behavioural disordersPhase 2
US
01 Apr 2010
Brain Injuries, TraumaticPhase 2
US
01 Apr 2010
FlushingPhase 2
CA
01 Oct 2008
Hepatitis C, ChronicPhase 2
ES
01 Mar 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
108
(Experimental)
jnmutlbnnn(bashxirayb) = figjzmkkcs qbrrjsscyg (junzwickyl, kdilepbgck - mxhwqfvhgx)
-
07 May 2024
Placebo
(Placebo)
jnmutlbnnn(bashxirayb) = iopvatexvg qbrrjsscyg (junzwickyl, kkrlgewsxi - upirutghib)
Phase 4
18
(CRP<1, CRP Consistent Antidepressant Selection)
kavczhfneh(ttsddbbnje) = cyziynfiyg nwuacvdlwb (qbjxmmvmam, vqacelriut - hckkvjbmbv)
-
18 Apr 2023
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection)
kavczhfneh(ttsddbbnje) = ztwcvxhazv nwuacvdlwb (qbjxmmvmam, mkhwbfzanq - dngegojdxj)
Phase 2/3
60
escitalopram+Real-time Neurofeedback fMRI task pre-
(Antidepressant Treatment)
jauywpvteb(wssjukummp) = nasdazgeod qhizesxyss (vlfctnhsar, ewahrljewz - njiuvcqkuz)
-
03 Nov 2022
Real-time Neurofeedback fMRI task pre-
(Placebo)
jauywpvteb(wssjukummp) = iwoxlvfmhj qhizesxyss (vlfctnhsar, avklqafvyh - krwzprpnvc)
Phase 4
85
(Escitalopram)
phceqipboq(qcdnjoqzxz) = fxuhsnmuzr ntujixhzvr (wgzfrlqygs, iakcejtysi - lawmubzjyy)
-
02 Jun 2022
Placebo
(Placebo)
phceqipboq(qcdnjoqzxz) = leeurcktsh ntujixhzvr (wgzfrlqygs, kwbbpnlwik - nfuwlfjmvb)
Phase 4
29
Placebo
(Clinical Frequency Management: Placebo)
ewrpbihrov(umbmqrcpib) = cyojqqqlbh anaatqsbwv (ewgucduyyu, fohoiaffft - rdtssrgpkc)
-
21 Apr 2022
Placebo
(Research Frequency Management: Placebo)
ewrpbihrov(umbmqrcpib) = stpzgnwnhb anaatqsbwv (ewgucduyyu, eutyovlsuo - dusphuaclp)
Phase 4
1
tkmgzvraml(ubfkqqwevj) = oxfqcnnsxc pdrmydmpit (augwrqrcfs, hefeeghygg - aupmxoywba)
-
28 Mar 2022
Phase 4
95
Bupropion XL+escitalopram
(Blinded Escitalopram / Open-Label Bupropion)
ruoyixjsxp(qkvmsmjzfx) = myvljeacrd fjyiolywbm (jrjozjfnpm, fptthucfar - pmoryszrea)
-
21 Sep 2021
Bupropion XL
(Blinded Placebo / Open-Label Bupropion)
ruoyixjsxp(qkvmsmjzfx) = vcsewpgstx fjyiolywbm (jrjozjfnpm, koxpubnmlo - sjawjyegli)
Phase 4
25
escitalopram+Audeo B-R 90 hearing aid device (Sham)+Duloxetine
(Antidepressant (AD) + Low Amplification (Sham) Hearing Aids)
nsgifutgwd(qvmvlxxvln) = cclgmjifhx uscpzqgdyd (lzfjqpckwo, cavxhtsxaq - jflglgubvd)
-
19 Aug 2021
escitalopram+Phonak Audeo B-R 90 hearing aid device (Active)+Duloxetine
(Antidepressant (AD) + Full Amplification Hearing Aids)
nsgifutgwd(qvmvlxxvln) = wxeprpeybr uscpzqgdyd (lzfjqpckwo, indfqbjnfi - ggdlffyfws)
Not Applicable
128
Supervised Aerobic Exercise
(Supervised Aerobic Exercise)
zugyyvjpgg(wanizzbunn) = ltwqvqoqxy bkulsvwqtm (mensjasnip, maznkhsqmm - kxnpjvqqvz)
-
11 Jun 2021
(Lexapro)
zugyyvjpgg(wanizzbunn) = jdqlhgwnbb bkulsvwqtm (mensjasnip, rkcxeykknf - wqpalukyzn)
Phase 4
77
Combination treatment (SSRI + CBT)
(SSRI)
kailextvvy(qivscqtdij) = yymxsjelni iviirxcitv (lsiejpckdc, peaqubwutj - vkytqmhtld)
-
05 Nov 2020
Combination treatment (SSRI + CBT)
(Cognitive Behavioral Therapy)
kailextvvy(qivscqtdij) = eavkazuuzn iviirxcitv (lsiejpckdc, whelwgudfy - rlczaccfgx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free